138 related articles for article (PubMed ID: 38213041)
1. Effectivity of Bromocriptine Administration Towards Prolactin Positive Breast Cancer Receiving Anthracycline-Based Chemotherapy: A Literature Review.
Permana MY; Sarwanti S; Fauziah S
Acta Med Indones; 2023 Oct; 55(4):465-474. PubMed ID: 38213041
[TBL] [Abstract][Full Text] [Related]
2. Mucuna pruriens (L.) DC chemo sensitize human breast cancer cells via downregulation of prolactin-mediated JAK2/STAT5A signaling.
Sinha S; Sharma S; Vora J; Shah H; Srivastava A; Shrivastava N
J Ethnopharmacol; 2018 May; 217():23-35. PubMed ID: 29427634
[TBL] [Abstract][Full Text] [Related]
3. Modulation of JAK-STAT Signaling by LNK: A Forgotten Oncogenic Pathway in Hormone Receptor-Positive Breast Cancer.
López-Mejía JA; Mantilla-Ollarves JC; Rocha-Zavaleta L
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834225
[TBL] [Abstract][Full Text] [Related]
4. Anthracycline Use for Early Stage Breast Cancer in the Modern Era: a Review.
Jasra S; Anampa J
Curr Treat Options Oncol; 2018 May; 19(6):30. PubMed ID: 29752560
[TBL] [Abstract][Full Text] [Related]
5. [Bromocriptine in chemotherapy-resistant, metastatic breast cancer. Results of the GO-MC-BROMO 2/82 AIO Study].
Holtkamp W; Nagel GA
Onkologie; 1988 Jun; 11(3):121-7. PubMed ID: 3045725
[TBL] [Abstract][Full Text] [Related]
6. Impact of heat stress on prolactin-mediated ovarian JAK-STAT signaling in postpubertal gilts.
Roach CM; Bidne KL; Romoser MR; Ross JW; Baumgard LH; Keating AF
J Anim Sci; 2022 Jul; 100(7):. PubMed ID: 35772766
[TBL] [Abstract][Full Text] [Related]
7. Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
Nikolényi A; Sükösd F; Kaizer L; Csörgo E; Vörös A; Uhercsák G; Ormándi K; Lázár G; Thurzó L; Brodowicz T; Kahán Z
Oncology; 2011; 80(3-4):269-77. PubMed ID: 21734419
[TBL] [Abstract][Full Text] [Related]
8. Prolactin has a pathogenic role in systemic lupus erythematosus.
Jara LJ; Medina G; Saavedra MA; Vera-Lastra O; Torres-Aguilar H; Navarro C; Vazquez Del Mercado M; Espinoza LR
Immunol Res; 2017 Apr; 65(2):512-523. PubMed ID: 28130617
[TBL] [Abstract][Full Text] [Related]
9. Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer.
Zaheed M; Wilcken N; Willson ML; O'Connell DL; Goodwin A
Cochrane Database Syst Rev; 2019 Feb; 2(2):CD012873. PubMed ID: 30776132
[TBL] [Abstract][Full Text] [Related]
10. A clinical study of taxotere versus taxotere plus the antiprolactinemic agent bromocriptine in metastatic breast cancer pretreated with anthracyclines.
Lissoni P; Bucovec R; Malugani F; Ardizzoia A; Villa S; Gardani GS; Vaghi M; Tancini G
Anticancer Res; 2002; 22(2B):1131-4. PubMed ID: 12168912
[TBL] [Abstract][Full Text] [Related]
11. The role of topoisomerase IIα in predicting sensitivity to anthracyclines in breast cancer patients: a meta-analysis of published literatures.
Du Y; Zhou Q; Yin W; Zhou L; Di G; Shen Z; Shao Z; Lu J
Breast Cancer Res Treat; 2011 Oct; 129(3):839-48. PubMed ID: 21809115
[TBL] [Abstract][Full Text] [Related]
12. Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer.
Konecny GE; Pauletti G; Untch M; Wang HJ; Möbus V; Kuhn W; Thomssen C; Harbeck N; Wang L; Apple S; Jänicke F; Slamon DJ
Breast Cancer Res Treat; 2010 Apr; 120(2):481-9. PubMed ID: 20130985
[TBL] [Abstract][Full Text] [Related]
13. Effects of dopamine d2 receptor agonists in a pituitary transplantation-induced hyperprolactinaemia/anovulation model in rats.
Moro M; Inada Y; Miyata H; Komatsu H; Kojima M; Tsujii H
Clin Exp Pharmacol Physiol; 2001 Aug; 28(8):651-8. PubMed ID: 11473532
[TBL] [Abstract][Full Text] [Related]
14. A pharmacophore-based classification better predicts the outcomes of HER2-negative breast cancer patients receiving the anthracycline- and/or taxane-based neoadjuvant chemotherapy.
Li X; Sun H; Liu Q; Liu Y; Hou Y; Jin W
Cancer Med; 2021 Jul; 10(13):4658-4674. PubMed ID: 34076352
[TBL] [Abstract][Full Text] [Related]
15. The Predictive and Prognostic Role of Topoisomerase IIα and Tissue Inhibitor of Metalloproteinases 1 Expression in Locally Advanced Breast Carcinoma of Egyptian Patients Treated With Anthracycline-based Neoadjuvant Chemotherapy.
El Rebey HS; Aiad HA; Abulkheir IL; Asaad NY; El-Wahed MM; Abulkasem FM; Mahmoud SF
Appl Immunohistochem Mol Morphol; 2016 Mar; 24(3):167-78. PubMed ID: 25710584
[TBL] [Abstract][Full Text] [Related]
16. Predictive factors for anthracycline-based chemotherapy for human breast cancer.
Miyoshi Y; Kurosumi M; Kurebayashi J; Matsuura N; Takahashi M; Tokunaga E; Egawa C; Masuda N; Kono S; Morimoto K; Kim SJ; Okishiro M; Yanagisawa T; Ueda S; Taguchi T; Tamaki Y; Noguchi S
Breast Cancer; 2010 Apr; 17(2):103-9. PubMed ID: 19657712
[TBL] [Abstract][Full Text] [Related]
17. Reflections on the development of resistance during therapy for advanced breast cancer. Implications of high levels of activity of docetaxel in anthracycline-resistant breast cancer patients.
Ravdin PM
Eur J Cancer; 1997 Aug; 33 Suppl 7():S7-10. PubMed ID: 9486096
[TBL] [Abstract][Full Text] [Related]
18. Pergolide : A Review of its Pharmacology and Therapeutic Use in Parkinson's Disease.
Markham A; Benfield P
CNS Drugs; 1997 Apr; 7(4):328-40. PubMed ID: 27520755
[TBL] [Abstract][Full Text] [Related]
19. Estrogen receptor α/prolactin receptor bilateral crosstalk promotes bromocriptine resistance in prolactinomas.
Xiao Z; Yang X; Zhang K; Liu Z; Shao Z; Song C; Wang X; Li Z
Int J Med Sci; 2020; 17(18):3174-3189. PubMed ID: 33173437
[TBL] [Abstract][Full Text] [Related]
20. The Pathological Response to Anthracycline is Associated with Topoisomerase IIα Gene Amplification in the HER2 Breast Cancer Subset.
Ishikawa T; Sasaki T; Tanabe M; Narui K; Kida K; Shimada K; Shimizu D; Yamada A; Morita S; Oba MS; Kawachi K; Nozawa A; Ichikawa Y; Takabe K; Endo I
J Surg Sci; 2014 Dec; 2(1):10-12. PubMed ID: 25642443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
